It has developed a line of the human exosomes that can deliver a medically relevant payload; viral vaccines, for example.
“Previously presented, unpublished data show that ReNeuron’s exosomes can be loaded with biologically active cargo and delivered preferentially to certain specific sites in the body,” the company said in a statement.
“This research is in its initial stages, the goal being to establish whether an increase in the potency of SARS-CoV-2 coronavirus vaccines in development can be enhanced in this way, utilising ReNeuron’s established expertise in exosome isolation, modification and manufacture at scale.”
The insight was provided alongside a wider update on progress in the face of the COVID-19 outbreak, which has led to wholesale lockdowns on both sides of the Atlantic.
The stem cell specialist said the disruption will inevitably lead to delays in the recruitment of patients to trials of its treatments for people with stroke disability and a degenerative eye condition called retinitis pigmentosa.
It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.
ReNeuron’s priority internal research, meanwhile, is progressing to “current timelines”. The firm said it is adhering to safety guidelines in the labs with a rota system and, where possible, work is being done from home.
“The safety of employees, suppliers, clinical trial participants and all other people with whom the company interacts is of over-riding importance to the company,” investors were told.
Finally, ReNeuron’s exclusive licensing partner in China, Shanghai Fosun, has recently filed to open clinical sites to take part in the ongoing PISCES III clinical trial in stroke disability.